08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

Aeolus preclinical data

In a mouse model of epilepsy, AEOL 11207 significantly reduced the frequency and duration of spontaneous behavioral seizures vs. vehicle-treated controls, but had no effect on seizure severity. Additionally, mice treated with the lipophilic metalloporphyrin...
07:00 , Jun 26, 2006 |  BC Week In Review  |  Clinical News

Aeolus preclinical data

In a mouse model of PD, AEOL 11207 had oral bioavailability of 80%. The neuroprotectant crossed the blood brain barrier and protected dopamine neurons in a dose-dependent manner. Also, data suggested that AEOL 11207 has...